AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
17
02
2022
accepted:
04
09
2022
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
2
12
2022
Statut:
epublish
Résumé
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nasal and paranasal sinuses. Dupilumab is a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, which are key and central drivers of type 2 inflammation. In clinical trials, dupilumab significantly improved objective and patient-reported measures of CRSwNP
Identifiants
pubmed: 36451848
doi: 10.1183/23120541.00085-2022
pii: 00085-2022
pmc: PMC9703146
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04959448']
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2022.
Déclaration de conflit d'intérêts
Conflict of interest: S. Siddiqui and H. Zhang are former Regeneron employees and may hold stock and/or stock options in Regeneron Pharmaceuticals, Inc. C. Bachert reports advisory board fees and speakers’ fees from Actobiotics, ALK, ASIT Biotech, AstraZeneca, GlaxoSmithKline, Intrexon, Novartis, Sanofi and Stallergenes Greer. A.M. Chaker reports research support, clinical study grants and advisory board fees/speaker honoraria (via Technical University Munich) from Abello, ALK, Allergopharma, ASIT Biotech, AstraZeneca, Bencard/Allergen Therapeutics, European Institute of Technology (EIT Health), German Federal Ministry of Education and Research, GlaxoSmithKline, Immunotek, LETI, Lofarma, Novartis, Regeneron Pharmaceuticals Inc., Roche, Sanofi and Zeller. J.K. Han reports advisory board fees from AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Inc., and Sanofi. P.W. Hellings reports advisory board fees from Regeneron Pharmaceuticals, Inc. and Sanofi. A.T. Peters reports advisory board fees and research grants from Regeneron Pharmaceuticals, Inc. and Sanofi, and consultant and research support from GlaxoSmithKline and Optinose. E. Heffler reports research grants from AstraZeneca, Boehringer Ingelheim, Circassia, GlaxoSmithKline, Nestlé Purina, Novartis, Sanofi, Teva and Valeas. S. Kamat, S. Nash and Y. Deniz are employees of, and may hold stock and/or stock options in, Regeneron Pharmaceuticals, Inc. A.H. Khan, L. De Prado Gomez, J.A. Jacob-Nara and P.J. Rowe are employees of, and may hold stock and/or stock options in, Sanofi.
Références
Laryngoscope. 2019 Sep;129(9):1969-1975
pubmed: 30720213
Rhinol Suppl. 2012 Mar;23:3 p preceding table of contents, 1-298
pubmed: 22764607
Nat Rev Dis Primers. 2020 Oct 29;6(1):86
pubmed: 33122665
Rhinology. 2021 Jun 1;59(3):301-311
pubmed: 33847325
Drugs. 2020 May;80(7):711-717
pubmed: 32240527
Rhinology. 2019 Oct 1;57(5):343-351
pubmed: 31318362
Lancet. 2019 Nov 2;394(10209):1638-1650
pubmed: 31543428
Allergy. 2022 Apr;77(4):1231-1244
pubmed: 34459002
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
J Allergy Clin Immunol Pract. 2019 Jan;7(1):156-164.e1
pubmed: 29800752
Allergy. 2020 May;75(5):1188-1204
pubmed: 31838750
Rhinology. 2020 Feb 20;58(Suppl S29):1-464
pubmed: 32077450
Rhinology. 2021 Apr 1;59(2):151-163
pubmed: 33459728
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8
pubmed: 24706856
Ann Otol Rhinol Laryngol. 2015 Aug;124(8):663-70
pubmed: 25743178
Respir Med. 2013 Aug;107(8):1141-51
pubmed: 23721684
J Asthma Allergy. 2021 Feb 11;14:127-134
pubmed: 33603409
Int Forum Allergy Rhinol. 2015 Jan;5(1):36-45
pubmed: 25236780
Ann Allergy Asthma Immunol. 2021 May;126(5):584-592.e1
pubmed: 33465455
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52
pubmed: 24706858
BMJ Open. 2015 Apr 29;5(4):e006680
pubmed: 25926143